Zealand Stock Performance

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZP</div>
ZEAL -- Denmark Stock  

DKK 241.40  3.60  1.47%

The firm maintains a market beta of 0.2197, which attests that as returns on market increase, Zealand Pharma returns are expected to increase less than the market. However, during bear market, the loss on holding Zealand Pharma will be expected to be smaller as well. Although it is extremely important to respect Zealand Pharma AS historical price patterns, it is better to be realistic regarding the information on equity current price history. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By examining Zealand Pharma AS technical indicators you can presently evaluate if the expected return of 0.0649% will be sustainable into the future. Zealand Pharma AS right now maintains a risk of 6.13%. Please check out Zealand Pharma AS Downside Deviation, Standard Deviation, Information Ratio, as well as the relationship between Coefficient Of Variation and Variance to decide if Zealand Pharma AS will be following its historical returns.

Search Stock Performance

 
Refresh
00

Zealand Pharma Risk-Adjusted Performance

Over the last 30 days Zealand Pharma AS has generated negative risk-adjusted returns adding no value to investors with long positions. Allthough quite persistent forward indicators, Zealand Pharma is not utilizing all of its potentials. The existing stock price mess, may contribute to short term losses for the partners.
Quick Ratio7.09
Fifty Two Week Low125.20
Target High Price190.72
Fifty Two Week High297.20
Target Low Price92.00

Zealand Pharma Relative Risk vs. Return Landscape

If you would invest  26,160  in Zealand Pharma AS on April 26, 2020 and sell it today you would lose (2,020)  from holding Zealand Pharma AS or give up 7.72% of portfolio value over 30 days. Zealand Pharma AS is generating 0.0649% of daily returns and assumes 6.1293% volatility on return distribution over the 30 days horizon. Simply put, 53% of equities are less volatile than Zealand Pharma and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, Zealand Pharma is expected to generate 1.49 times more return on investment than the market. However, the company is 1.49 times more volatile than its market benchmark. It trades about 0.01 of its potential returns per unit of risk. The DOW is currently generating roughly -0.01 per unit of risk.

Zealand Pharma Market Risk Analysis

Sharpe Ratio = 0.0106
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
ZEALHuge
Risk
Negative Returns

Zealand Pharma Stock Performance Indicators

Estimated Market Risk
 6.13
  actual daily
 
 53 %
of total potential
 
5353
Expected Return
 0.06
  actual daily
 
 1 %
of total potential
 
11
Risk-Adjusted Return
 0.01
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Zealand Pharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zealand Pharma by adding it to a well-diversified portfolio.

Zealand Pharma Alerts

Equity Alerts and Improvement Suggestions

Zealand Pharma AS has very high historical volatility over the last 30 days
The company reported revenue of 42.96 M. Net Loss for the year was (508.24 M) with profit before overhead, payroll, taxes, and interest of 40.92 M.
ZEALAND PHARMA has accumulated about 1.54 B in cash with (390.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 43.11.
Roughly 64.0% of the company outstanding shares are owned by institutional investors
Check out Your Current Watchlist. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page